The uraemic toxin phenylacetic acid inhibits osteoblastic proliferation and differentiation: an implication for the pathogenesis of low turnover bone in chronic renal failure.
暂无分享,去创建一个
[1] K. Kurokawa,et al. Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] S. Ralston,et al. Regulation of bone mass and bone turnover by neuronal nitric oxide synthase. , 2004, Endocrinology.
[3] M. Petersson,et al. Inhibited anabolic effect of insulin-like growth factor-I on stromal bone marrow cells in endothelial nitric oxide synthase-knockout mice. , 2004, Acta physiologica Scandinavica.
[4] H. Hassan,et al. Regulation of PTH1 receptor expression by uremic ultrafiltrate in UMR 106-01 osteoblast-like cells. , 2004, Kidney international.
[5] J. Jankowski,et al. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. , 2003, The Journal of clinical investigation.
[6] Raymond Vanholder,et al. Review on uremic toxins: classification, concentration, and interindividual variability. , 2003, Kidney international.
[7] R. Kitazawa,et al. Decrease in vitamin D receptor and calcium-sensing receptor in highly proliferative parathyroid adenomas. , 2003, European journal of endocrinology.
[8] R. Vanholder,et al. Effects of uremic ultrafiltrate on the regulation of the parathyroid cell cycle by calcitriol. , 2003, Kidney international.
[9] K. Martin,et al. Metabolic acidosis up-regulates PTH/PTHrP receptors in UMR 106-01 osteoblast-like cells. , 2002, Kidney international.
[10] K. Chihara,et al. Smad3 Promotes Alkaline Phosphatase Activity and Mineralization of Osteoblastic MC3T3‐E1 Cells , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[11] A. Freemont,et al. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. , 2000, Kidney international.
[12] S. Mohan,et al. Evaluation of IGF System Component Levels and Mitogenic Activity of Uremic Serum on Normal Human Osteoblasts , 2000, Nephron.
[13] J M Polak,et al. Mechanical Strain Stimulates Nitric Oxide Production by Rapid Activation of Endothelial Nitric Oxide Synthase in Osteocytes , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[14] M. Inaba,et al. Lymphoblastoid interferon-alpha downregulates parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor expression in human osteoblastic cells (Saos-2). , 1998, Bone.
[15] S. Ralston,et al. Estrogen upregulates endothelial constitutive nitric oxide synthase expression in human osteoblast-like cells. , 1998, Endocrinology.
[16] K. Martin,et al. Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells. , 1996, Kidney international.
[17] H. Jüppner,et al. Down-regulation of the receptor for parathyroid hormone (PTH) and PTH-related peptide by transforming growth factor-beta in primary fetal rat osteoblasts. , 1995, Endocrinology.
[18] R. Vanholder,et al. Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. , 1995, The Journal of clinical investigation.
[19] P. W. Johnston,et al. Nitric oxide: A cytokine‐induced regulator of bone resorption , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] B. Lacour,et al. Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats. , 1995, Kidney international.
[21] D Hernández,et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. , 1995, Kidney international.
[22] H. Jüppner,et al. Rapid desensitization of parathyroid hormone dependent adenylate cyclase in perifused human osteosarcoma cells (SaOS-2). , 1994, Biochimica et biophysica acta.
[23] P. Nibbering,et al. Inducible production of nitric oxide in osteoblast-like cells and in fetal mouse bone explants is associated with suppression of osteoclastic bone resorption. , 1994, The Journal of clinical investigation.
[24] K. Chihara,et al. Cross‐talk of parathyroid hormone‐responsive dual signal transduction systems in osteoblastic osteosarcoma cells: Its role in PTH‐induced homologous desensitization of intracellular calcium response , 1994, Journal of cellular physiology.
[25] R. Vanholder,et al. Mechanism of decreased intestinal calcitriol receptor concentration in renal failure. , 1993, The American journal of physiology.
[26] Y. Pei,et al. The spectrum of bone disease in end-stage renal failure--an evolving disorder. , 1993, Kidney international.
[27] M. Monier‐Faugere,et al. Risk of adynamic bone disease in dialyzed patients. , 1992, Kidney international. Supplement.
[28] G. Mundy,et al. Tumor necrosis factor and interleukin 1 inhibit parathyroid hormone‐responsive adenylate cyclase in clonal osteoblast‐like cell by down‐regulating parathyroid hormone receptors , 1992 .
[29] L. Quarles,et al. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. , 1992, The Journal of clinical endocrinology and metabolism.
[30] T. Martin,et al. A potent inhibitor of osteoclastic bone resorption within a highly conserved pentapeptide region of parathyroid hormone-related protein; PTHrP[107-111]. , 1991, Endocrinology.
[31] M. Fukase,et al. Protein kinase C is involved in PTH-induced homologous desensitization by directly affecting PTH receptor in the osteoblastic osteosarcoma cells. , 1991, Endocrinology.
[32] G. Howard,et al. Identification of a low molecular weight inhibitor of osteoblast mitogenesis in uremic plasma. , 1991, Kidney international.
[33] R. Nissenson,et al. Desensitization of parathyroid hormone receptors on cultured bone cells , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[34] R. Jilka,et al. Homologous and Heterologous Control of Bone Cell Adenosine 3′,5′-Monophosphate Response to Hormones by Parathormone, Prostaglandin E2, Calcitonin, and 1,25-hydroxycholecalciferol* , 1980 .
[35] S. Massry,et al. Skeletal resistance to parathyroid hormone in renal failure. Studies in 105 human subjects. , 1973, Annals of internal medicine.
[36] R. Dziak,et al. Effects of tumor necrosis factor alpha on parathyroid hormone-induced increases in osteoblastic cell cyclic AMP , 2007, Calcified Tissue International.
[37] J. Polak,et al. Endothelial nitric oxide synthase gene-deficient mice demonstrate marked retardation in postnatal bone formation, reduced bone volume, and defects in osteoblast maturation and activity. , 2001, The American journal of pathology.
[38] D. Reid,et al. Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. , 2001 .
[39] L. Kedes,et al. PTH-PTHrP receptor mRNA is downregulated in chronic renal failure. , 1994, American journal of nephrology.
[40] B. Descamps-Latscha,et al. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. , 1990, Kidney international.